Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $4.0 billion.

  • BeOne Medicines' Cash & Equivalents rose 4940.67% to $4.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year increase of 4940.67%. This contributed to the annual value of $2.6 billion for FY2024, which is 1716.34% down from last year.
  • As of Q3 2025, BeOne Medicines' Cash & Equivalents stood at $4.0 billion, which was up 4940.67% from $2.8 billion recorded in Q2 2025.
  • BeOne Medicines' Cash & Equivalents' 5-year high stood at $4.5 billion during Q2 2022, with a 5-year trough of $1.4 billion in Q3 2021.
  • In the last 5 years, BeOne Medicines' Cash & Equivalents had a median value of $3.1 billion in 2023 and averaged $3.1 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 21663.07% in 2021, then plummeted by 2691.83% in 2023.
  • Quarter analysis of 5 years shows BeOne Medicines' Cash & Equivalents stood at $4.4 billion in 2021, then decreased by 11.57% to $3.9 billion in 2022, then fell by 18.03% to $3.2 billion in 2023, then dropped by 17.16% to $2.6 billion in 2024, then soared by 53.64% to $4.0 billion in 2025.
  • Its Cash & Equivalents stands at $4.0 billion for Q3 2025, versus $2.8 billion for Q2 2025 and $2.5 billion for Q1 2025.